<DOC>
	<DOCNO>NCT00190918</DOCNO>
	<brief_summary>This phase II study evaluate activity Pemetrexed patient diagnose low risk Gestational Trophoblastic Tumor ( GTT ) fail prior treatment .</brief_summary>
	<brief_title>A Trial Patients With Gestational Trophoblastic Disease</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Hydatidiform Mole</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Persistent recurrent low risk Gestational Trophoblastic Tumor ( GTT ) WHO score 26 ( reevaluated time relapse Histologically confirm complete partial mole initial evacuation Patients mild moderate renal insufficiency avoid take NSAIDs short elimination halflives period 2 day , day , 2 day follow administration pemetrexed . All patient take NSAIDs longer halflives , interrupt dose least 5 day , day , 2 day follow pemetrexed administration . Folic Acid ( 3501000 microgram ) must give daily begin approximately 57 day prior first dose pemetrexed continue daily 3 week last dose study therapy . Vitamin B12 ( 1000 microgram ) administer intramuscular injection approximately 1 2 week prior first dose pemetrexed repeat approximately every 9 week 3 week last dose study therapy . Previous treatment include chemotherapy actinomycin D methotrexate ( +/ folinic acid ) . Patients 8 metastatic lesion identify Patients metastasis liver , spleen , brain , kidney GI tract</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>